There is a 2800 per cent profit in the price of an IV set at which manufacturers sell to hospitals and the Maximum Retail Price and that indicates a need for a relook into the pricing and profit issues, Maharashtra FDA Commissioner Tukaram Mundhe told NDTV in an exclusive interview today.
While pharma or any other industry will not work to incur losses, Tukaram Mundhe said there needs to be transparency. “A trade margin of 2800 per cent is not acceptable, either as a consumer or as a hospital or as a regulator,” he told NDTV.
“Basically there has to be a fair trade, fair margin of profit. But it cannot be opaque. It cannot be unacceptable to the consumers, to the regulators and of course it cannot be acceptable to the manufacturers as well. They have to have profit. But it has to be fair, transparent and ethical,” he added.
Because they have to run business.
he said there needs to be transparency While pharma or any other industry will not work to incur losses. “A trade margin of 2800 per cent is by any terms not acceptable, either as a consumer or as a hospital or as a regulator,” he told NDTV. It needs to be seen “what they are expecting, how much input is there, how much profit margin they are looking at and at the same time as a regulator, the pricing authority, government will look into what is the margin that should be allowed,” he said.
